

A NEW IMAGING AGENT AS MARKER OF RENAL FUNCTION

ERG\NEO

L'AVENIR EST FAIT D'AUDACE

Development of new imaging agent as marker of renal function.

PRESENTATION

Several causes lead to Chronic kidney diseases (CKD) increased incidence. CKD generate renal fibrosis, responsible for chronic kidney failure, a major public health issue. There are limitations to renal function evaluation and fibrosis treatment : lack of precise and non invasive tools to evaluate renal function and antifibrotic drugs efficacy.

Our solution is to use MRI imaging agent as marker of renal function. It could be used both as an imaging marker to assist in the diagnosis and monitoring of chronic renal pathologies related to fibrosis, and as a preclinical and clinical research tool for the development of an antifibrotic agent, as an alternative to the monitoring of biomarkers requiring cumbersome biopsies.

DEVELOPMENT PHASE

☑ In vitro & In vivo Proof of Concept

Imaging agent - Renal fibrosis
Renal function evaluation - Drug efficacy testing

INTELLECTUAL PROPERTY

4 Patent Application pending : CA, EP, JP and US.

APPLICATIONS

- Renal fibrosis diagnostic
- Renal function Evaluation and follow up
- Drug efficacy evaluation

CONTACT

☎ +33 (0)1 44 23 21 50
✉ industriels@erganeo.com
Ref. project : 254

COMPETITIVE ADVANTAGES

- Better precision
- Non invasive evaluation
- Better care
- Monitoring new therapies